Ribocure Pharmaceuticals AB

https://www.ribocure.com

Suzhou Ribo Life Science Co., Ltd. is an innovative clinical stage R&D company devoted to the development of nucleic acid drugs and related products based on the RNA interference (RNAi) technology. With its innovative R&D capabilities with vertically integrated technological platforms, Ribo has built a strong product pipeline, aiming to make contribution to the treatment of serious diseases with unmet medical needs. As a subsidiary of Ribo Life Science Co., Ltd., Ribocure Pharmaceuticals AB is dedicated to globalized development of life-saving oligonucleotide therapies, with focus on development of assets and pipeline as well as new target ideas and on building innovative capacities to conduct clinical trials and developing siRNA drugs to address real unmet medical needs globally *

	Start	2024-01-03 existent
	Group	Ribo Life Science (Group)
	Industry	RNAi technology
	Industry 2	RNAi drug (RNAi therapeutic)

	Region	Mölndal
	Country	Sweden
	City	n. a. Mölndal
		Address record changed: 2024-01-03

Basic data	Employees	n. a.

		* Document for »About Section«: Boehringer Ingelheim. (1/3/24). "Press Release: Boehringer Ingelheim Partners with Ribo to Develop New Treatments for People with Liver Diseases". Ingelheim, Mölndal & Kunshan.

		Record changed: 2024-02-12

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for Ribo Life Science (Group)

[1] Boehringer Ingelheim. (1/3/24). "Press Release: Boehringer Ingelheim Partners with Ribo to Develop New Treatments for People with Liver Diseases". Ingelheim, Mölndal & Kunshan....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]